However, our experience from working with breast cancers is that infiltrating CD163+ TAMs are quite frequent, but CD169+ TAMs are not, indicating that only a minority of the CD163+ TAMs (M2-like TAMs) are CD169+ (9, 51). The gene discussed is SIGLEC1; the disease is breast cancer.